Last updated: 2026-11-15 20:36:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Johnson & Johnson (JNJ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $285.89, with a market capitalization of $687.89B and a P/E ratio of 42.74. Over the past 52 weeks, its price has ranged from $195.90 to $288.11. This page covers its latest market performance, valuation, price trends and company information.
$687.89B | |
$285.00 | |
$288.03 | |
$283.53 | |
$283.52 | |
4.00M | |
7.12M | |
42.74 | |
$288.11 | |
$195.90 | |
1.85% | |
12-28 |
Johnson & Johnson (JNJ) last closed at $285.89 as of 2026-11-14 00:53:56, up 1.11% ($3.15) from the previous close of $283.52.
During the latest regular trading session, JNJ traded between $283.53 and $288.03, with a volume of 4.00M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Johnson & Johnson (JNJ) moved from $272.32 to $285.89, representing a gain of 4.98% ($13.56).
The stock traded between $265.55 and $288.11 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 7.62 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 97.6%
JNJ is currently trading at $285.89, placing it 97.6% of the way from its 52-week low of $195.90 to its 52-week high of $288.11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 140,800 |
| CEO | Joaquin Duato |
| Founded | 1886 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Johnson & Johnson.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 24, 2026 |
| Payment Date | Dec 8, 2026 |
| Dividend Per Share | $1.34 |
Latest news related to Johnson & Johnson and JNJ stock.
The article recommends five dividend stocks suitable for long-term buy-and-hold investors: Johnson & Johnson, Medtronic, Procter & Gamble, Federal Realty Investment Trust, and Realty Income. All five companies have strong dividend track records with at least 32 years of consecutive annual increases, combined with well-run underlying businesses that generate reliable income streams.
As 2026 winds down, the article analyzes four key sector ETFs heading into 2027. Technology stocks have pulled back 14% from October highs after AI companies missed earnings, but the sector remains reasonably valued. Financial stocks are mixed, with insurance outperforming while banks struggle amid tepid loan demand. Energy stocks surged 40% YTD on oil prices but face headwinds as crude may have peaked around $90/barrel. Healthcare stocks are up 21% but appear slightly overvalued at current levels.
As tech stocks struggle post-election, investors are rotating into defensive sectors like healthcare. The State Street Healthcare Select Sector SPDR ETF (XLV) has gained 23% in 2026, outperforming the S&P 500's 11% return. Healthcare's inelastic demand makes it attractive during market volatility, though investors should consider dollar-cost averaging given the recent run-up.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
AbbVie reported strong Q3 2026 results with immunology revenues rising 16.6% to $9.2 billion, driven by blockbuster drugs Skyrizi (up 22.9%) and Rinvoq (up 24.3%), offsetting Humira's 30.6% decline due to biosimilar competition. The company raised 2026 sales forecasts for both drugs, expecting combined growth exceeding 20%, with new indications in inflammatory bowel disease and dermatology providing additional growth opportunities.
Eligible investors can buy real shares of Johnson & Johnson (JNJ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Johnson & Johnson
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to JNJ, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between JNJ shares and USD.
JNJ Shares to USD
1.00 JNJ shares = 285.885 USD
Calculations are estimates based on the latest available price and are for reference only.
